Liverpool ChiroChem Ltd (LCC) is a chemical technology innovator, on a mission to 
accelerate the discovery and development of high-quality drugs. LCC provide access to 3D chemical space to support orthogonal hit-ID (VLS, DEL, FBLD) and lead optimisation. LCC has designed a 3D-rich, stereodefined 1.4-Bn member Ultra-Large Virtual Library, which is synthetically tractable through using reaction based enumeration of their proprietary BB, co-located with their parallel synthesis laboratory.
LCC helps teams develop high-quality drugs by providing access to a 3D chemical space to support orthogonal hit-ID (VLS, DEL, FBLD) and lead optimization. With the integration of this 3D stereo defined Ultra-Large Virtual Library (ULVL) into the QuADD platform, research teams can identify candidates that are immediately available for further computational research, screening, or wet lab testing. This can accelerate the computational drug discovery process by orders of magnitude, shortening a part of the typical timeframe normally measured in months or years to one measured in days or even minutes.
To read more about the partnership, see the joint press release from August of 2024.
